US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
OptimizeRx Corporation - Common Stock
(NQ:
OPRX
)
8.570
+0.180 (+2.15%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OptimizeRx Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
September 22, 2026
Expands programmatic access to 800,000 verified prescribers directly in the EHR workflow, making OptimizeRx’s point of care inventory directly available to advertisers using The Trade Desk
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
September 14, 2026
New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
September 08, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Corp (NASDAQ:OPRX) Beats Q1 Estimates But Slashes 2026 Revenue Guidance
↗
May 12, 2026
Via
Chartmill
OptimizeRx Corp (NASDAQ:OPRX) Beats Q4 Earnings Estimates but Offers Cautious 2026 Outlook
↗
March 05, 2026
Via
Chartmill
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
September 02, 2026
Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technology
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
AI software revenue grew 25% despite overall quarterly decline from customer inactivity.
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
OptimizeRx Q2 Earnings Call Highlights
↗
August 12, 2026
OptimizeRx (NASDAQ:OPRX) reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its...
Via
MarketBeat
Topics
Earnings
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
August 12, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
August 12, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
July 29, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
July 23, 2026
Leading pharmaceutical marketing executive joins leadership team to accelerate innovation and strengthen partnerships across the life sciences industry
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
June 30, 2026
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
June 25, 2026
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts
From
OptimizeRx Corporation
Via
GlobeNewswire
MissionIRNewsBreaks – OptimizeRx Corp. (NASDAQ: OPRX) Secures $35 Million Senior Credit Facility
June 11, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
OptimizeRx to Participate in Upcoming Investor Conferences
June 01, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx’s Authenticated EHR Network
May 21, 2026
Powered by OptimizeRx’s new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx (OPRX) Q1 2026 Earnings Transcript
↗
May 14, 2026
OptimizeRx (OPRX) Q1 2026 Earnings Transcript
Via
The Motley Fool
OptimizeRx Q1 Earnings Call Highlights
↗
May 12, 2026
OptimizeRx (NASDAQ:OPRX) reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life...
Via
MarketBeat
Topics
Earnings
OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
May 12, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
May 11, 2026
Expands life sciences marketers’ reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx’s trusted EHR network for the first time
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report
April 29, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
April 28, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
Discover the top movers in Wednesday's pre-market session.
↗
March 18, 2026
Via
Chartmill
OptimizeRx (OPRX) Q4 2025 Earnings Call Transcript
↗
March 05, 2026
OptimizeRx (OPRX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
Whetstone Capital Exits GitLab as Enterprises Rethink AI-Driven Software Development Tools
↗
February 26, 2026
Whetstone Capital Advisors has sold its stake in GitLab, a unified DevOps platform competing in the fast-changing market for AI-assisted coding and secure software delivery. As companies look at...
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Whetstone Dumps 79,000 monday.com Shares Worth $15.3 Million
↗
February 21, 2026
This cloud-based software provider serves organizations worldwide with modular tools for work management and collaboration.
Via
The Motley Fool
Topics
Artificial Intelligence
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
February 05, 2026
From
OptimizeRx Corporation
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
